Pharma Manufacturing

Be sure to read this Editors' (re)View, where our editors discuss pharma happenings. See what you may have missed. This week, Greg Slabodkin explores WuXi AppTec’s announcement that it has agreed to sell WuXi Advanced Therapies, its cell and gene therapy unit, to New York-headquartered private equity firm Altaris. Altaris, LLC #EditorsReview #WuXiAppTec #WuXiAdvancedTherapies #Altaris #pharmanews #pharmamanufacturing #pharmaindustry #genetherapy #privateequityfirm https://lnkd.in/gMCccBKS

2024 was a “transformative year marked by groundbreaking milestones and continued maturation” for the cell and gene therapy sector, according to a year in review from the Alliance for Regenerative Medicine (ARM). #2025 #2024 #AllianceforRegenerativeMedicine #cellandgenetherapy #celltherapy #genetherapy #ARM #pharmanews #pharmamanufacturing https://lnkd.in/gFFXWUdx

The resiliency of biopharmaceutical supply chains has never been more important and in many ways more vulnerable. Despite the potential for disruptions, 75% of global life sciences executives are “positive to cautiously positive” about 2025, according to a survey published earlier this month by the Deloitte US Center for Health Solutions.  #biopharma #supplychains #globallifesciences #2025 #biopharmaceutical #pharmanews #pharmamanufacturing #biopharmasector https://lnkd.in/gEgVtN39

2024 was a breakthrough year for cell and gene therapies, with the first FDA-approved engineered cell therapy for solid tumors and the first FDA approval for a gene therapy directly administered to the brain. While these potentially curative therapies offer hope to millions of patients, they remain complex and difficult to manufacture at scale. Read more about the challenges facing cell and gene therapy manufacturing in 2025 with the link below. #Cellandgenetherapies #CGT #manufacturing #pharmamanufacturing #2025 #FDAapproval #genetherapy #celltherapy #solidtumors https://lnkd.in/gijRmqYV

WuXi AppTec announced it has entered into an agreement to sell the U.S. and U.K. based operations of WuXi Advanced Therapies, its cell and gene therapy unit, to New York-headquartered healthcare investment firm Altaris. Altaris, LLC #WuXiAppTec #WuXiAdvancedTherapies #Altaris #genetherapy #pharmanews #pharmamanufacturing https://lnkd.in/gbKJSsN3

Indian contract development and manufacturing organization Akums Drugs & Pharmaceuticals announced it has signed a $200 million agreement with an undisclosed “leading global pharma company” to manufacture select oral liquid formulations for the European market. Akums Drugs& Pharmaceuticals Ltd #contractdevelopment #AkumsDrugsandPharmaceuticals #leadingglobalpharmacompany #oralliquidformulations #EuropeanMarket #pharmanews #pharmamanufacturing https://lnkd.in/gMKRvAmX

According to a new report from GlobalData, Samsung Bioepis has the largest number of approved products in the biosimilars market, but Celltrion leads the overall biosimilar deals landscape. Celltrion Inc #Celltrion #SamsungBioepis #biosimilars #approvedproducts #biopharma #biosimilarsmarket #biopharmacompany #pharmanews #pharmamanufacturing https://lnkd.in/gZ2BT7iE

See what you may have missed this week in pharma with our Editors' (re)View, where our editors discuss notable happenings in the industry. This week, Greg Slabodkin tackles Novo Holdings' $16.5B acquisition of Catalent which took the global contract development and manufacturing organization private. The buyout is a one-off the likes of which the industry may not see again. Read the full article with the link below! Catalent Pharma Solutions #NovoHoldings #NovoNordisk #Catalent #CatalentPharmaSolutions #acquisition #contractdevelopment #privateorganization #buyout #pharmaindustry #pharmanews #pharmamanufacturing #editorsreview https://lnkd.in/gasVRfm2

While contract development and manufacturing organizations faced headwinds in 2024, the outlook next year for the CDMO space is cautiously optimistic based on some encouraging macroeconomic and industry-specific trends, according to analysts and stakeholders. Read the full article from our own Greg Slabodkin with the link below. #contractdevelopmentandmanufacturingorganizations #CDMOs #CDMOoutlook #2025 #industrytrends #pharmamanufacturingtrends #pharmamanufacturing #CDMOsector https://lnkd.in/ds-qhdZh

Lifecore Biomedical announced that it has been selected by biotech company Nirsum Laboratories to provide CDMO services supporting Nirsum’s clinical development of its lead development candidate, NRS-033, a novel treatment for opioid use disorder and alcohol use disorder. Nirsum Labs #LifecoreBiomedical #NirsumLaboratories #CDMOservices #clinicaldevelopment #opioidusedisorder #alcoholusedisorder #pharmanews #pharmamanufacturing https://lnkd.in/dT9-vrN4